Respiatory Viral Infections in Patients with Multiple Myeloma
NCT06810115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 219
Last updated 2025-02-05
Summary
Respiratory viruses are known to be a major cause of morbodity in multiple myeloma patients but prospective long-term sudies are lacking. We analysed 219 multiple myeloma patients that had 554 nasopharingeal swabs with 58 documented viral episodes. Respiratory viruses studied were rhinovirus, enterovirus, parainflienza, respirator, syncytial virus, metapneumovirus, coronavirus, bocavirus, influenza A, influenza B. Clinical data were extracted from a prospectively entered database, medical records were reviewed. We have prospectively studiend patients until May 2019 when we gathered survival data. Lastly because of Covid-19 pandemic when almost no other viral infections were isolated, we analysed clinical course of respiratory infections in patients with multiple myeloma after the pandemic.
Conditions
- Multiple Mieloma
- Respiratory Viral Infections
Interventions
- OTHER
-
Viral PCR test
Viral PCR test regardles of symptoms
Sponsors & Collaborators
-
University Medical Centre Ljubljana
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-10-01
- Primary Completion
- 2019-05-01
- Completion
- 2024-10-01
More Related Trials
-
Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03619252 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma
NCT06925958 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05855122 ·Status: UNKNOWN ·Phase: PHASE4
-
Non-invasive MRD Assessment in Multiple Myeloma
NCT05625971 ·Status: COMPLETED
-
Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
NCT06205823 ·Status: ACTIVE_NOT_RECRUITING
-
Multiple Myeloma Patient Registry
NCT03180853 ·Status: TERMINATED
-
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma
NCT05448196 ·Status: COMPLETED ·Phase: NA
-
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045 ·Status: COMPLETED ·Phase: PHASE2
-
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01087008 ·Status: COMPLETED ·Phase: PHASE4
-
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
NCT06888856 ·Status: NOT_YET_RECRUITING
-
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
NCT06151717 ·Status: COMPLETED
-
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251 ·Status: RECRUITING ·Phase: PHASE1
-
Telemonitoring Among Patients With Multiple Myeloma
NCT05964270 ·Status: UNKNOWN ·Phase: NA
-
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
NCT01421186 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT03908138 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
NCT05698888 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
NCT06799676 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
NCT03100877 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
NCT06366802 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
NCT00773747 ·Status: COMPLETED ·Phase: PHASE3
-
Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
NCT01665014 ·Status: UNKNOWN ·Phase: PHASE2
-
Bleeding in Multiple Myeloma
NCT06482931 ·Status: NOT_YET_RECRUITING